134 related articles for article (PubMed ID: 37425790)
1. Engineering Human Pluripotent Stem Cell Lines to Evade Xenogeneic Transplantation Barriers.
Pizzato HA; Alonso-Guallart P; Woods J; Johannesson B; Connelly JP; Fehniger TA; Atkinson JP; Pruett-Miller SM; Monsma FJ; Bhattacharya D
bioRxiv; 2023 Jun; ():. PubMed ID: 37425790
[TBL] [Abstract][Full Text] [Related]
2. Engineering human pluripotent stem cell lines to evade xenogeneic transplantation barriers.
Pizzato HA; Alonso-Guallart P; Woods J; Connelly JP; Fehniger TA; Atkinson JP; Pruett-Miller SM; Monsma FJ; Bhattacharya D
Stem Cell Reports; 2024 Feb; 19(2):299-313. PubMed ID: 38215755
[TBL] [Abstract][Full Text] [Related]
3. Human Induced Pluripotent Stem Cells Are Targets for Allogeneic and Autologous Natural Killer (NK) Cells and Killing Is Partly Mediated by the Activating NK Receptor DNAM-1.
Kruse V; Hamann C; Monecke S; Cyganek L; Elsner L; Hübscher D; Walter L; Streckfuss-Bömeke K; Guan K; Dressel R
PLoS One; 2015; 10(5):e0125544. PubMed ID: 25950680
[TBL] [Abstract][Full Text] [Related]
4. Natural Killer Cells Prevent the Formation of Teratomas Derived From Human Induced Pluripotent Stem Cells.
Benabdallah B; Désaulniers-Langevin C; Colas C; Li Y; Rousseau G; Guimond JV; Haddad E; Beauséjour C
Front Immunol; 2019; 10():2580. PubMed ID: 31787975
[TBL] [Abstract][Full Text] [Related]
5. Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques.
Hu X; White K; Olroyd AG; DeJesus R; Dominguez AA; Dowdle WE; Friera AM; Young C; Wells F; Chu EY; Ito CE; Krishnapura H; Jain S; Ankala R; McGill TJ; Lin A; Egenberger K; Gagnon A; Michael Rukstalis J; Hogrebe NJ; Gattis C; Basco R; Millman JR; Kievit P; Davis MM; Lanier LL; Connolly AJ; Deuse T; Schrepfer S
Nat Biotechnol; 2024 Mar; 42(3):413-423. PubMed ID: 37156915
[TBL] [Abstract][Full Text] [Related]
6. Generation of universal and hypoimmunogenic human pluripotent stem cells.
Ye Q; Sung TC; Yang JM; Ling QD; He Y; Higuchi A
Cell Prolif; 2020 Dec; 53(12):e12946. PubMed ID: 33174655
[TBL] [Abstract][Full Text] [Related]
7. Exploitation of herpesvirus immune evasion strategies to modify the immunogenicity of human mesenchymal stem cell transplants.
de la Garza-Rodea AS; Verweij MC; Boersma H; van der Velde-van Dijke I; de Vries AA; Hoeben RC; van Bekkum DW; Wiertz EJ; Knaän-Shanzer S
PLoS One; 2011 Jan; 6(1):e14493. PubMed ID: 21253016
[TBL] [Abstract][Full Text] [Related]
8. Generation of hypoimmunogenic human pluripotent stem cells via expression of membrane-bound and secreted β2m-HLA-G fusion proteins.
Shi L; Li W; Liu Y; Chen Z; Hui Y; Hao P; Xu X; Zhang S; Feng H; Zhang B; Zhou S; Li N; Xiao L; Liu L; Ma L; Zhang X
Stem Cells; 2020 Nov; 38(11):1423-1437. PubMed ID: 32930470
[TBL] [Abstract][Full Text] [Related]
9. Effects of histocompatibility and host immune responses on the tumorigenicity of pluripotent stem cells.
Dressel R
Semin Immunopathol; 2011 Nov; 33(6):573-91. PubMed ID: 21461989
[TBL] [Abstract][Full Text] [Related]
10. Humanized mouse models with endogenously developed human natural killer cells for in vivo immunogenicity testing of HLA class I-edited iPSC-derived cells.
Flahou C; Morishima T; Higashi N; Hayashi Y; Xu H; Wang B; Zhang C; Ninomiya A; Qiu WY; Yuzuriha A; Suzuki D; Nakamura S; Manz M; Kaneko S; Hotta A; Takizawa H; Eto K; Sugimoto N
Biochem Biophys Res Commun; 2023 Jun; 662():76-83. PubMed ID: 37099813
[TBL] [Abstract][Full Text] [Related]
11. Pluripotent stem cells are highly susceptible targets for syngeneic, allogeneic, and xenogeneic natural killer cells.
Dressel R; Nolte J; Elsner L; Novota P; Guan K; Streckfuss-Bömeke K; Hasenfuss G; Jaenisch R; Engel W
FASEB J; 2010 Jul; 24(7):2164-77. PubMed ID: 20145206
[TBL] [Abstract][Full Text] [Related]
12. CRISPR-Cas9 immune-evasive hESCs are rejected following transplantation into immunocompetent mice.
Frederiksen HR; Glantz A; Vøls KK; Skov S; Tveden-Nyborg P; Freude K; Doehn U
Front Genome Ed; 2024; 6():1403395. PubMed ID: 38863835
[TBL] [Abstract][Full Text] [Related]
13. Targeted Disruption of the β2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells.
Wang D; Quan Y; Yan Q; Morales JE; Wetsel RA
Stem Cells Transl Med; 2015 Oct; 4(10):1234-45. PubMed ID: 26285657
[TBL] [Abstract][Full Text] [Related]
14. Efficient Killing of Murine Pluripotent Stem Cells by Natural Killer (NK) Cells Requires Activation by Cytokines and Partly Depends on the Activating NK Receptor NKG2D.
Gröschel C; Hübscher D; Nolte J; Monecke S; Sasse A; Elsner L; Paulus W; Trenkwalder C; Polić B; Mansouri A; Guan K; Dressel R
Front Immunol; 2017; 8():870. PubMed ID: 28890717
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic versus xenogeneic immune reaction to bioengineered skin grafts.
Erdag G; Morgan JR
Cell Transplant; 2004; 13(6):701-12. PubMed ID: 15648740
[TBL] [Abstract][Full Text] [Related]
16. Multipotent adult germ-line stem cells, like other pluripotent stem cells, can be killed by cytotoxic T lymphocytes despite low expression of major histocompatibility complex class I molecules.
Dressel R; Guan K; Nolte J; Elsner L; Monecke S; Nayernia K; Hasenfuss G; Engel W
Biol Direct; 2009 Aug; 4():31. PubMed ID: 19715575
[TBL] [Abstract][Full Text] [Related]
17. Natural killer cell-activating receptor NKG2D mediates innate immune targeting of allogeneic neural progenitor cell grafts.
Phillips LK; Gould EA; Babu H; Krams SM; Palmer TD; Martinez OM
Stem Cells; 2013 Sep; 31(9):1829-39. PubMed ID: 23733329
[TBL] [Abstract][Full Text] [Related]
18. Fine tuning of natural killer cell specificity and maintenance of self tolerance in MHC class I-deficient mice.
Salcedo M; Andersson M; Lemieux S; Van Kaer L; Chambers BJ; Ljunggren HG
Eur J Immunol; 1998 Apr; 28(4):1315-21. PubMed ID: 9565371
[TBL] [Abstract][Full Text] [Related]
19. Engineered human pluripotent stem cell-derived natural killer cells with PD-L1 responsive immunological memory for enhanced immunotherapeutic efficacy.
Chang Y; Jin G; Luo W; Luo Q; Jung J; Hummel SN; Torregrosa-Allen S; Elzey BD; Low PS; Lian XL; Bao X
Bioact Mater; 2023 Sep; 27():168-180. PubMed ID: 37091063
[TBL] [Abstract][Full Text] [Related]
20. Development of experimental tumors formed by mouse and human embryonic stem and teratocarcinoma cells after subcutaneous and intraperitoneal transplantations into immunodeficient and immunocompetent mice.
Gordeeva OF; Nikonova TM
Cell Transplant; 2013; 22(10):1901-14. PubMed ID: 23051679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
